Nature Search

Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay

Tumour-informed ctDNA is a sensitive potential biomarker for treatment response in breast cancer. Here, the authors use longitudinal sampling to predict disease recurrence during neoadjuvant and adjuvant treatment.

Mitchell J. Elliott
Philippe Echelard
David W. Cescon
ResearchOpen Access21 Feb 2025
Nature Communications

Volume: 16, P: 1-13
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Paul Pharoah and colleagues report the results of a large genome-wide association study of ovarian cancer. They identify new susceptibility loci for different epithelial ovarian cancer histotypes and use integrated analyses of genes and regulatory features at each locus to predict candidate susceptibility genes, including OBFC1.

Catherine M Phelan
Karoline B Kuchenbaecker
Paul D P Pharoah
Research27 Mar 2017
Nature Genetics

Volume: 49, P: 680-691
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

Seock-Ah Im
Javier Cortes
Peter Schmid
ResearchOpen Access12 Sept 2024
npj Breast Cancer

Volume: 10, P: 1-9
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

CDK4/6 inhibitors have improved outcomes for patients with ER+ breast cancer, however, those with loss of RB1 function often fail to respond. Here, the authors identify a vulnerability of ER + /RB1- breast cancer on PRMT5 and via dual blockade of ER and PRMT5 therapeutically target this in patient-derived xenograft models.

Chang-Ching Lin
Tsung-Cheng Chang
Carlos L. Arteaga
ResearchOpen Access13 Mar 2024
Nature Communications

Volume: 15, P: 1-16
Pembrolizumab and chemotherapy in high-risk, early-stage, ER⁺/HER2⁻ breast cancer: a randomized phase 3 trial

In this prespecified interim analysis of the KEYNOTE-756 phase 3 trial, pembrolizumab and chemotherapy treatment of patients with high-risk, early-stage, estrogen receptor-positive/human epidermal growth factor receptor-negative breast cancer improved the pathological complete response rate compared with chemotherapy alone.

Fatima Cardoso
Joyce O’Shaughnessy
Aditya Bardia
ResearchOpen Access21 Jan 2025
Nature Medicine

Volume: 31, P: 442-448
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

G-quadruplex stabilizers, including CX-5461, exhibit synthetic lethality with loss of BRCA1/2 in preclinical models. Here the authors report the results of a phase I study of CX-5461 in patients with solid tumors enriched for DNA-repair deficiencies.

John Hilton
Karen Gelmon
David W. Cescon
ResearchOpen Access24 Jun 2022
Nature Communications

Volume: 13, P: 1-12
Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids

Patient-derived tumour organoids are important preclinical models but suffer from variability from the use of basement-membrane extract and cell contamination. Here, the authors report on the development of mimetic nanofibrilar hydrogel which supports tumour organoid growth with reduced batch variability and cell contamination.

Elisabeth Prince
Jennifer Cruickshank
Eugenia Kumacheva
ResearchOpen Access18 Mar 2022
Nature Communications

Volume: 13, P: 1-12
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer

Type I PRMT inhibition elicits potent antitumor activity associated with increased interferon response and intron-retained dsRNA accumulation, suggesting its potential combination with immune checkpoint inhibitors for cancer treatment.

Qin Wu
David Y. Nie
Cheryl H. Arrowsmith
ResearchOpen Access16 May 2022
Nature Chemical Biology

Volume: 18, P: 821-830
Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy

Jesús Fuentes-Antrás
Mitchell J. Elliott
David W. Cescon
ResearchOpen Access19 Jul 2025
npj Breast Cancer

Volume: 11, P: 1-12
Author Correction: Gene isoforms as expression-based biomarkers predictive of drug response in vitro

Zhaleh Safikhani
Petr Smirnov
Benjamin Haibe-Kains
Amendments and CorrectionsOpen Access09 Jan 2018
Nature Communications

Volume: 9, P: 1
Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins

Statins are promising for breast cancer therapy; dipyridamole can potentiate their effects, but is contraindicated in some cases. Here, the authors develop a pharmacogenomics pipeline to predict other compounds that potentiate statins, and validate the top candidates in cell line screens and 3D cultures.

Jenna E. van Leeuwen
Wail Ba-Alawi
Deena M. A. Gendoo
ResearchOpen Access24 Oct 2022
Nature Communications

Volume: 13, P: 1-17
FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells

Yuqing Feng
Philip Barbulescu
Rossanna C. Pezo
ResearchOpen Access02 Jul 2025
Scientific Reports

Volume: 15, P: 1-10
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer

Triple negative breast cancer is a deadly form of breast cancer with limited therapeutic options. Here the authors show the efficacy of GLUT1 pharmacological inhibition against a subset of tumors expressing RB1, thereby identifying RB1 protein level as a biomarker of sensitivity to anti-GLUT1 therapy.

Qin Wu
Wail ba-alawi
Cheryl H. Arrowsmith
ResearchOpen Access21 Aug 2020
Nature Communications

Volume: 11, P: 1-12
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours

Stabilization of DNA quadruplex structures (G4) is lethal for cells with a compromised DNA repair pathway. Here, the authors show that CX-5461, a small molecule in clinical trials as RNA polymerase inhibitor, has G4-stablization properties and can be repurposed to target DNA repair-defective cancers cells.

Hong Xu
Marco Di Antonio
Samuel Aparicio
ResearchOpen Access17 Feb 2017
Nature Communications

Volume: 8, P: 1-18
Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study

Mitchell J. Elliott
Marguerite Ennis
David W. Cescon
ResearchOpen Access12 Jun 2020
npj Breast Cancer

Volume: 6, P: 1-6
No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer

Zachary Veitch
Domen Ribnikar
David W. Cescon
Research20 Dec 2021
British Journal of Cancer

Volume: 126, P: 881-888
Gene isoforms as expression-based biomarkers predictive of drug response in vitro

Altered mRNA splicing features in many cancers, but it has not been linked to drug response. Here, with their meta-analytic framework, the authors analyse pharmacogenomic data to identify isoform-based biomarkers predictive of in vitro drug response, and show them to frequently be strong predictors.

Zhaleh Safikhani
Petr Smirnov
Benjamin Haibe-Kains
ResearchOpen Access24 Oct 2017
Nature Communications

Volume: 8, P: 1-11
Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer

Mathieu Lupien and colleagues report an enrichment of somatic mutations at the ESR1 cis-regulatory region in 7% of ESR1-positive breast cancers. They find that the activity of the recurrently mutated ESR1 enhancer is also influenced by breast cancer risk–associated SNPs.

Swneke D Bailey
Kinjal Desai
Mathieu Lupien
Research29 Aug 2016
Nature Genetics

Volume: 48, P: 1260-1266
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification

Christopher Zhang
Benson Z. Wu
Kelsie L. Thu
ResearchOpen Access24 Aug 2024
Cancer Gene Therapy

Volume: 31, P: 1559-1570
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Zachary W. Veitch
David W. Cescon
Philippe L. Bedard
ResearchOpen Access15 Jul 2019
British Journal of Cancer

Volume: 121, P: 318-324
The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THRα1) Antagonism

Mitchell J. Elliott
Katarzyna J. Jerzak
David W. Cescon
ResearchOpen Access08 Nov 2018
Scientific Reports

Volume: 8, P: 1-10
Circulating tumor DNA and liquid biopsy in oncology

Evaluation of circulating tumor DNA in blood has emerged as a powerful technology for oncology research. Lillian Siu and colleagues review the potential applications of liquid biopsy, highlighting clinical-trial designs to establish its clinical utility.

David W. Cescon
Scott V. Bratman
Lillian L. Siu
Reviews20 Mar 2020
Nature Cancer

Volume: 1, P: 276-290
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

David B. Page
Harry Bear
Sylvia Adams
ReviewsOpen Access08 Oct 2019
npj Breast Cancer

Volume: 5, P: 1-9

Search

Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Pembrolizumab and chemotherapy in high-risk, early-stage, ER⁺/HER2⁻ breast cancer: a randomized phase 3 trial

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids

PRMT inhibition induces a viral mimicry response in triple-negative breast cancer

Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy

Author Correction: Gene isoforms as expression-based biomarkers predictive of drug response in vitro

Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins

FAM72A promotes UNG2 degradation and mutagenesis in human cancer cells

GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours

Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study

No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer

Gene isoforms as expression-based biomarkers predictive of drug response in vitro

Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer

Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THRα1) Antagonism

Circulating tumor DNA and liquid biopsy in oncology

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

Search

Quick links

Search

Filter By:

Search

Quick links